A concise review of pulmonary sarcoidosis

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 5, 2011, Pages 573-581

  Baughman, Robert P ^a   Culver, Daniel A ^b   Judson, Marc A ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

HLA; Infliximab; L fgren syndrome; Mycobacterium; Pulmonary hypertension

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CORTICOSTEROID; DEXMETHYLPHENIDATE; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE F 18; FOLIC ACID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

DNA POLYMORPHISM; FATIGUE; FORCED VITAL CAPACITY; GRANULOMATOUS INFLAMMATION; HEART DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LUNG GRANULOMA; LYMPH NODE BIOPSY; NEEDLE BIOPSY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SARCOIDOSIS;

HUMANS; SARCOIDOSIS, PULMONARY;

EID: 79952221689     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201006-0865CI     Document Type: Review

References (134)

1. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, Du BR, Eklund A, Kitaichi M, Lynch J, Rizzato G, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149-173. (Pubitemid 29469097)
2. Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 2005;35:166-174. (Pubitemid 41713956)
3. Moller DR, Chen ES. Genetic basis of remitting sarcoidosis: triumph of the trimolecular complex? Am J Respir Cell Mol Biol 2002;27:391-395.
4. Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, Pandey JP, Newman LS, Magira E, Beznik-Cizman B, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003;73:720-735. (Pubitemid 37271878)
5. Rybicki BA, Maliarik MJ, Poisson LM, Sheffer R, Chen KM, Major M, Chase GA, Iannuzzi MC. The major histocompatibility complex gene region and sarcoidosis susceptibility in African Americans. Am J Respir Crit Care Med 2003;167:444-449. (Pubitemid 36216430)
6. Grunewald J, Eklund A. Lofgren's syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med 2009;179:307-312.
7. Grunewald J, Brynedal B, Darlington P, Nisell M, Cederlund K, Hillert J, Eklund A. Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients. Respir Res. 2010;11:25.
8. Sato H, Grutters JC, Pantelidis P, Mizzon AN, Ahmad T, Van Houte AJ, Lammers JW, van den Bosch JM, Welsh KI, du Bois RM. HLA-DQB1* 0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002;27:406-412.
9. Schurmann M, Reichel P, Muller-Myhsok B, Schlaak M, Muller-Quernheim J, Schwinger E. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med 2001;164:840-846. (Pubitemid 32881922)
10. Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, Nagy M, Gaede KI, Franke A, Haesler R, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005;37:357-364.
11. Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC. The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. Am J Hum Genet 2005;77:491-499. (Pubitemid 41192655)
12. Iannuzzi MC, Iyengar SK, Gray-McGuire C, Elston RC, Baughman RP, Donohue JF, Hirst K, Judson MA, Kavuru MS, Maliarik MJ, et al. Genome-wide search for sarcoidosis susceptibility genes in African Americans. Genes Immun 2005;6:509-518. (Pubitemid 43090509)
13. Hofmann S, Franke A, Fischer A, Jacobs G, Nothnagel M, Gaede KI, Schurmann M, Muller-Quernheim J, Krawczak M, Rosenstiel P, et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet 2008;40:1103-1106.
14. Fischer A, Nothnagel M, Schurmann M, Muller-Quernheim J, Schreiber S, Hofmann S. A genome-wide linkage analysis in 181 German sarcoidosis families using clustered bi-allelic markers. Chest 2010;138:151-157.
15. Moller DR, Forman JD, Liu MC, Noble PW, Greenlee BM, Vyas P, Holden DA, Forrester JM, Lazarus A, Wysocka M, et al. Enhanced expression of IL-12 associated with Th 1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996;156:4952-4960. (Pubitemid 26174485)
16. Ziegenhagen MW, Rothe E, Zissel G, Muller-Quernheim J. Exagerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:185-190.
17. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990;115:36-42. (Pubitemid 20044133)
18. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, Du BR, Albera C, Brutsche M, Davis G, Donohue JF, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802. (Pubitemid 44511661)
19. Crouser ED, Culver DA, Knox KS, Julian MW, Shao G, Abraham S, Liyanarachchi S, Macre JE, Wewers MD, Gavrilin MA, et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 2009;179:929-938.
20. Rosenbaum JT, Pasadhika S, Crouser ED, Choi D, Harrington CA, Lewis JA, Austin CR, Diebel TN, Vance EE, Braziel RM, et al. Hypothesis: sarcoidosis is a STAT1-mediated disease. Clin Immunol 2009;132:174-183.
21. Sundar KM, Carveth HJ, Gosselin MV, Beatty PG, Colby TV, Hoidal JR. Granulomatous pneumonitis following bone marrow transplantation. Bone Marrow Transplant 2001;28:627-630. (Pubitemid 32976367)
22. Milman N, Andersen CB, Burton CM, Iversen M. Recurrent sarcoid granulomas in a transplanted lung derive from recipient immune cells. Eur Respir J 2005;26:549-552. (Pubitemid 41264219)
23. Eishi Y, Suga M, Ishige I, Kobayashi D, Yamada T, Takemura T, Takizawa T, Koike M, Kudoh S, Costabel U, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 2002;40:198-204. (Pubitemid 34027624)
24. Song Z, Marzilli L, Greenlee BM, Chen ES, Silver RF, Askin FB, Teirstein AS, Zhang Y, Cotter RJ, Moller DR. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005;201:755-767. (Pubitemid 40395121)
25. Chen ES, Wahlstrom J, Song Z, Willett MH, Wiken M, Yung RC, West EE, McDyer JF, Zhang Y, Eklund A, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008;181:8784-8796.
26. Drake WP, Dhason MS, Nadaf M, Shepherd BE, Vadivelu S, Hajizadeh R, Newman LS, Kalams SA. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun 2007;75:527-530. (Pubitemid 46047932)
27. Oswald-Richter KA, Culver DA, Hawkins C, Hajizadeh R, Abraham S, Shepherd BE, Jenkins CA, Judson MA, Drake WP. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun 2009;77:3740-3748.
28. Allen SS, Evans W, Carlisle J, Hajizadeh R, Nadaf M, Shepherd BE, Pride DT, Johnson JE, Drake WP. Superoxide dismutase A antigens derived from molecular analysis of sarcoidosis granulomas elicit systemic Th-1 immune responses. Respir Res 2008;9:36.
29. Carlisle J, Evans W, Hajizadeh R, Nadaf M, Shepherd B, Ott RD, Richter K, Drake W. Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells. Clin Exp Immunol 2007;150:460-468. (Pubitemid 350098733)
30. Hajizadeh R, Sato H, Carlisle J, Nadaf MT, Evans W, Shepherd BE, Miller RF, Kalams SA, Drake WP. Mycobacterium tuberculosis Antigen 85A induces Th-1 immune responses in systemic sarcoidosis. J Clin Immunol 2007;27:445-454. (Pubitemid 46906652)
31. Moller DR. Potential etiologic agents in sarcoidosis. Proc Am Thorac Soc 2007;4:465-468. (Pubitemid 47435374)
32. Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, Groshong SD, Zhang Y, Tuder RM, Moller DR. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 2010;181:360-373.
33. Rothkrantz-Kos S, Dieijen-Visser MP, Mulder PG, Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003;49:1510-1517. (Pubitemid 37011740)
34. Swaisgood CM, Oswald-Richter K, Moeller SD, Klemenc JM, Ruple LM, Farver CF, Drake JM, Culver DA, Drake WP. Development of a sarcoidosis murine lung granuloma model using Mycobacterium sodA. Am J Respir Cell Mol Biol (In press)
35. Taflin C, Miyara M, Nochy D, Valeyre D, Naccache JM, Altare F, Salek-Peyron P, Badoual C, Bruneval P, Haroche J, et al. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol 2009;174:497-508.
36. Ho LP, Urban BC, Thickett DR, Davies RJ, McMichael AJ. Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. Lancet. 2005;365:1062-1072. (Pubitemid 40386784)
37. Manouvrier-Hanu S, Puech B, Piette F, Boute-Benejean O, Desbonnet A, Duquesnoy B, Farriaux JP. Blau syndrome of granulomatous arthritis, iritis, and skin rash: a new family and review of the literature. Am. J Med Genet 1998;76:217-221. (Pubitemid 28108807)
38. Brinker H, Pederson NT. Immunologic marker patterns in granulomatous lymph node lesions. Histopathology 1989;15:495-503.
39. Judson MA. The diagnosis of sarcoidosis. Clin Chest Med 2008;29:415-427, viii.
40. Judson MA, Thompson BW, Rabin DL, Steimel J, Knatterud GL, Lackland DT, Rose C, Rand CS, Baughman RP, Teirstein AS. The diagnostic pathway to sarcoidosis. Chest 2003;123:406-412. (Pubitemid 36269422)
41. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager HJ, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, et al; A Case Control Etiologic Study of Sarcoidosis (ACCESS) Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-1889.
42. Loddenkemper R, Kloppenborg A, Schoenfeld N, Grosser H, Costabel U. Clinical findings in 715 patients with newly detected pulmonary sarcoidosis-results of a cooperative study in former West Germany and Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft fur die Therapie von Lungenkrankheitan. Sarcoidosis Vasc Diffuse Lung Dis 1998;15:178-182.
43. Pietinalho A, Ohmichi M, Hiraga Y, Lofroos AB, Selroos O. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis 1996;13:159-166.
44. Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med 2010;31:409-418.
45. Hansell DM, Milne DG, Wilsher ML, Wells AU. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology 1998;209:697-704. (Pubitemid 28564901)
46. Handa T, Nagai S, Fushimi Y, Miki S, Ohta K, Niimi A, Mishima M, Izumi T. Clinical and radiographic indices associated with airflow limitation in patients with sarcoidosis. Chest 2006;130:1851-1856. (Pubitemid 46033445)
47. Harrison BD, Shaylor JM, Stokes TC, Wilkes AR. Airflow limitation in sarcoidosis-a study of pulmonary function in 107 patients with newly diagnosed disease. Respir Med 1991;85:59-64.
48. Sharma OP, Johnson R. Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest 1988;94:343-346.
49. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest 2001;120:881-886. (Pubitemid 32885464)
50. Chambellan A, Turbie P, Nunes H, Brauner M, Battesti JP, Valeyre D. Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution. Chest 2005;127:472-481. (Pubitemid 40229305)
51. Baughman RP, Iannuzzi MC, Lower EE, Moller DR, Balkissoon RC, Winget DB, Judson MA. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:198-204.
52. Yeager H, Rossman MD, Baughman RP, Teirstein AS, Judson MA, Rabin DL, Iannuzzi MC, Rose C, Bresnitz EA, DePalo L, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:147-153. (Pubitemid 41020022)
53. Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005;128:1483-1489. (Pubitemid 41324436)
54. Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:108-116. (Pubitemid 47471829)
55. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. BMJ 1961;4:1165-1172.
56. Judson MA, Baughman RP, Thompson BW, Teirstein AS, Terrin ML, Rossman MD, Yeager H Jr, McLennan G, Bresnitz EA, DePalo L, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:204-211. (Pubitemid 37351542)
57. Nagai S, Shigematsu M, Hamada K, Izumi T. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med 1999;5:293-298.
58. Baughman RP, Selroos O. Evidence-based approach to the treatment of sarcoidosis. In: Gibson PG, Abramson M, Wood-Baker R, Volmick J, Hensley M, Costabel U, editors. Evidence-based respiratory medicine. Malden, MA: Blackwell Publishing Ltd.; 2005. pp. 491-508.
59. Baughman RP, Shipley R, Desai S, Drent M, Judson MA, Costabel U, du Bois RM, Kavuru M, Schlenker-Herceg R, Flavin S, et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2009;136:526-535.
60. Judson MA, Gilbert GE, Rodgers JK, Greer CF, Schabel SI. The utility of the chest radiograph in diagnosing exacerbations of pulmonary sarcoidosis. Respirology 2008;13:97-102.
61. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007;132:207-213. (Pubitemid 47068223)
62. Garwood S, Judson MA, Silvestri G, Hoda R, Fraig M, Doelken P. Endobronchial ultrasound for the diagnosis of pulmonary sarcoidosis. Chest 2007;132:1298-1304. (Pubitemid 47621007)
63. Tremblay A, Stather DR, Maceachern P, Khalil M, Field SK. A randomized controlled trial of standard vs endobronchial ultrasonography-guided transbronchial needle aspiration in patients with suspected sarcoidosis. Chest 2009;136:340-346.
64. Israel HL, Goldstein RA. Hepatic granulomatosis and sarcoidosis. Ann Intern Med 1973;79:669-678.
65. Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm 2009;17:160-169.
66. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr; ACCESS Research group. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:75-86.
67. Silverstein E, Pertschuk LP, Friedland J. Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas. Proc Natl Acad Sci USA 1979;76:6646-6648. (Pubitemid 10163456)
68. Studdy PR, Bird R, Neville E, James DG. Biochemical findings in sarcoidosis. J Clin Pathol 1980;33:528-533. (Pubitemid 10039079)
69. Studdy PR, James DG. The specificity and sensitivity of serum angiotensin-converting enzyme in sarcoidosis and other diseases. In: Chretien J, Marsac J, Saltiel JC, editors. Sarcoidosis. Paris: Pergamon Press; 1983. pp. 332-344.
70. Lieberman J, Nosal A, Schlessner A, Sastre-Foken A. Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis 1979;120:329-335. (Pubitemid 9245947)
71. Tomita H, Ina Y, Sugiura Y, Sato S, Kawaguchi H, Morishita M, Yamamoto M, Ueda R. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med 1997;156:255-259. (Pubitemid 27293198)
72. Pietinalho A, Furuya K, Yamaguchi E, Kawakami Y, Selroos O. The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J 1999;13:723-726. (Pubitemid 29234768)
73. Lieberman J, Schleissner LA, Nosal A, Sastre A, Mishkin FS. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67gallium scans, chest roentgenograms, and pulmonary function. Chest 1983;84:522-528.
74. DeRemee RA, Rohrbach MS. Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis. Ann Intern Med 1980;92:361-365. (Pubitemid 10154811)
75. Pietinalho A, Ohmichi M, Lofroos AB, Hiraga Y, Selroos O. The prognosis of sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:158-166.
76. Gronhagen-Riska C, Selroos O, Niemisto M. Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respir Dis 1980;61:113-122.
77. Baughman RP, Ploysongsang Y, Roberts RD, Srivastava L. Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis 1983;128:631-633. (Pubitemid 13014110)
78. Bargagli E, Bianchi N, Margollicci M, Olivieri C, Luddi A, Coviello G, Grosso S, Rottoli P. Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity. Scand J Clin Lab Invest 2008;68:479-483.
79. Ziegenhagen MW, Rothe ME, Schlaak M, Muller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003;21:407-413. (Pubitemid 36336197)
80. Bargagli E, Mazzi A, Rottoli P. Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med 2008;29:445-458, (viii.).
81. Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008;35:1537-1543.
82. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007;132:1949-1953.
83. Nunes H, Brillet PY, Valeyre D, Brauner MW, Wells AU. Imaging in sarcoidosis. Semin Respir Crit Care Med 2007;28:102-120. (Pubitemid 46364275)
84. Braun JJ, Imperiale A, Riehm S, Veillon F. Imaging in sinonasal sarcoidosis: CT, MRI, (67)Gallium scintigraphy and (18)F-FDG PET/CT features. J Neuroradiol 2009;73:172-181.
85. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999;138:299-302. (Pubitemid 29379681)
86. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-1211. (Pubitemid 9092005)
87. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, Machac J, Teirstein A. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-1435. (Pubitemid 351893001)
88. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, Crijns HJ. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 2005;128:30-35. (Pubitemid 40994450)
89. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, Harrison BD. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996;51:238-247.
90. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997;111:623-631.
91. Baughman RP, Judson MA, Teirstein A, Yeager H, Rossman M, Knatterud GL, Thompson B. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006;99:307-315.
92. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005;CD001114.
93. Paramothayan S, Lasserson T, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2003;CD003536.
94. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schunemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006;129:174-181. (Pubitemid 43265259)
95. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008;29:533-548.
96. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008;25:76-89.
97. Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS, Drent M. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008;31:1189-1196.
98. Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller WJ, Sands BE. A double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:201-208. (Pubitemid 47596315)
99. Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009;135:468-476.
100. Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009;103:268-273.
101. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009;72:337-340.
102. Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman RP. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010;27:49-56.
103. Almodovar R, Izquierdo M, Zarco P, Javier QF, Mazzucchelli R, Steen B. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2007;25:99-101. (Pubitemid 46477494)
104. Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009;48:883-886.
105. Sweiss NJ, Baughman RP. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon? J Rheumatol 2007;34:2129-2131. (Pubitemid 350076868)
106. Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, Barnathan ES. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol 2008;9:155-161. (Pubitemid 351572057)
107. de Kleijn WP, de Vries J, Lower EE, Elfferich MD, Baughman RP, Drent M. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009;15:499-506.
108. de Kleijn WPE, Elfferich MDP, de Vries J, Jonker GJ, Lower EE, Baughman RP, King TE Jr, Drent M. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis 2009;26:92-97.
109. Gvozdenovic BS, Mihailovic-Vucinic V, Ilic-Dudvarski A, Zugic V, Judson MA. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008;102:1636-1642.
110. Elfferich MD, Nelemans PJ, Ponds RW, de Vries J, Wijnen PA, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010;80:212-219.
111. Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:235. (Pubitemid 41668362)
112. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008;133:1189-1195. (Pubitemid 351685525)
113. Diaz-Guzman E, Farver C, Parambil J, Culver DA. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med 2008;29:549-563. (Pubitemid 351778207)
114. Handa T, Nagai S, Miki S, Fushimi Y, Ohta K, Mishima M, Izumi T. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006;129:1246-1252.
115. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008;32:296-302.
116. Rizzato G, Pezzano A, Sala G, Merlini R, Ladelli L, Tansini G, Montanari G, Bertoli L. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis 1983;64:121-128. (Pubitemid 13181058)
117. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005;25:783-788. (Pubitemid 40667674)
118. Nunes H, Humbert M, Capron F, Brauner M, Sitbon O, Battesti JP, Simonneau G, Valeyre D. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006;61:68-74. (Pubitemid 43106981)
119. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010;138:1078-1085.
120. Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006;130:1481-1488. (Pubitemid 44786743)
121. Baughman RP, Judson MA, Lower EE, Highland K, Kwon S, Craft N, Engel PJ. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009;26:110-120.
122. Barnett CF, Bonura EJ, Nathan SD, Ahmad S, Shlobin OA, Osei K, Zaiman AL, Hassoun PM, Moller DR, Barnett SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension: a two-center experience. Chest 2009;135:1455-1461.
123. Pietinalho A, Lindholm A, Haahtela T, Tukiainen P, Selroos O. Inhaled budesonide for treatment of pulmonary sarcoidosis: results of a double-blind, placebo-controlled, multicentre study. Eur Respir J 1996;9:406s.
124. McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010;339:1-4.
125. Johns CJ, Michele TM. The clinical management of sarcoidosis: a 50-year experience at the Johns Hopkins hospital. Medicine 1999;78:65-111.
126. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:60-66. (Pubitemid 30157757)
127. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995;155:846-851.
128. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 2002;8:470-476. (Pubitemid 34836955)
129. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krundieck CL, Alarcon GS. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 1994;121:833-841.
130. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999;14:1117-1122.
131. Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:87-92.
132. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:43-48. (Pubitemid 38533813)
133. Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003;148:147-148. (Pubitemid 36114877)
134. Moudgil A, Przygodzki RM, Kher KK. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol 2006;21:281-285. (Pubitemid 43115886)